SLC22A17

Across TCGA pan-cancer cohorts, SLC22A17 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SLC22A17 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher SLC22A17 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC22A17 expression acts as an unfavorable survival marker.

PRAD, UCEC, and LIHC are the cancer types where SLC22A17 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	OS	Median	All	0.363	0.787	.004	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SLC22A17–PRAD (DFS)

Open the PRAD breakdown →